The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer. The Food and Drug Administration (FDA) has ...
Sarepta SRPT announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (“PRV”) for $102 million. The monetization of the PRV will enable management to develop more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback